Panomifene

Chemical compound
Panomifene
Clinical data
Other namesGYKI-13504; EGIS-5650
Identifiers
  • 2-[2-[4-[(E)-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol
CAS Number
  • 77599-17-8
PubChem CID
  • 3033654
ChemSpider
  • 2298282
UNII
  • GCW5E728OC
ChEMBL
  • ChEMBL2105273
Chemical and physical data
FormulaC25H24F3NO2
Molar mass427.467 g·mol−1
3D model (JSmol)
  • Interactive image
  • C1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\C(F)(F)F)/C3=CC=C(C=C3)OCCNCCO
InChI
  • InChI=1S/C25H24F3NO2/c26-25(27,28)24(21-9-5-2-6-10-21)23(19-7-3-1-4-8-19)20-11-13-22(14-12-20)31-18-16-29-15-17-30/h1-14,29-30H,15-18H2/b24-23+
  • Key:MHXVDXXARZCVRK-WCWDXBQESA-N

Panomifene (INN; developmental codes GYKI 13504 and EGIS 5650) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group related to tamoxifen that was under development as an antineoplastic agent by Egis Pharmaceuticals and IVAX Drug Research Institute in the 1990s for the treatment of breast cancer, but it was never marketed.[1][2][3][4][5][6] It reached phase II clinical trials before development was terminated.[2] The drug was described in 1981.[1]

References

  1. ^ a b Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 930–. ISBN 978-1-4757-2085-3.
  2. ^ a b "Panomifene". AdisInsight. Springer Nature Switzerland AG.
  3. ^ von Angerer E (6 December 2012). "Antiestrogens and Partial Agonists". In Oettel M, Schillinger E (eds.). Estrogens and Antiestrogens I: Physiology and Mechanisms of Action of Estrogens and Antiestrogens. Springer Science & Business Media. pp. 60–. ISBN 978-3-642-58616-3.
  4. ^ Sitruk-Ware R (6 December 2012). "Pharmacological Different Administration Routes - Oral vs Transdermal". In Oettel M, Schillinger E (eds.). Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Springer Science & Business Media. pp. 292–. ISBN 978-3-642-60107-1.
  5. ^ Koike T, Akita M (18 October 2014). "Visible-Light-Induced Redox Reactions by Ruthenium Photoredox Catalyst". In Dixneuf PH, Bruneau C (eds.). Ruthenium in Catalysis. Springer. pp. 385–. ISBN 978-3-319-08482-4.
  6. ^ Borvendég J, Hermann I, Csuka O (1996). "Antiestrogens, antiandrogens". Acta Physiologica Hungarica. 84 (4): 405–406. PMID 9328614.
  • v
  • t
  • e
ERTooltip Estrogen receptor
Agonists
Mixed
(SERMsTooltip Selective estrogen receptor modulators)
Antagonists
  • Coregulator-binding modulators: ERX-11
GPERTooltip G protein-coupled estrogen receptor
Agonists
Antagonists
Unknown
See also
Receptor/signaling modulators
Estrogens and antiestrogens
Androgen receptor modulators
Progesterone receptor modulators
List of estrogens
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e